Lymph node dissection in curative gastrectomy for advanced gastric cancer

Shigeyuki Tamura, Atsushi Takeno, Hirofumi Miki, Shigeyuki Tamura, Atsushi Takeno, Hirofumi Miki

Abstract

Gastric cancer is one of the most common causes of cancer-related death worldwide. Surgical resection with lymph node dissection is the only potentially curative therapy for gastric cancer. However, the appropriate extent of lymph node dissection accompanied by gastrectomy for cancer remains controversial. In East Asian countries, especially in Japan and Korea, D2 lymph node dissection has been regularly performed as a standard procedure. In Western countries, surgeons perform gastrectomy with D1 dissection only because D2 is associated with high mortality and morbidity compared to those associated with D1 alone but does not improve the 5-year survival rate. However, more recent studies have demonstrated that western surgeons can be trained to perform D2 lymphadenectomies on western patients with a lower morbidity and mortality. When extensive D2 lymph node dissection is preformed safely, there may be some benefit to D2 dissection even in western countries. In this paper, we present an update on the current literature regarding the extent of lymphadenectomy for advanced gastric cancer.

Figures

Figure 1
Figure 1
Lymph node station numbers according to the Japanese classification of gastric cancer of the 14th edition reproduced form [12] with permission.
Figure 2
Figure 2
Lymph node dissection according to the Japanese gastric cancer treatment guideline 2010 of the 3rd edition reproduced form [14] with permission. D1 distal gastrectomy consists of LN dissection of station nos. 1, 3, 4sb, 4d, 5, 6, and 7 and D1 total gastrectomy consists of station nos. 1–6 and 7 (blue circle). Yellow circles indicate the lymph nodes that belong to D1+, and red circles indicate those to D2.

References

    1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. International Journal of Cancer. 1999;83(1):18–29.
    1. Lordick F, Siewert JR. Perioperative chemotherapy vs. surgery alone in resectable gastroesophsageal carcinoma. Results of the MAGIC Study. Chirun. 2006;77:1166–1167.
    1. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. The New England Journal of Medicine. 2001;345(10):725–730.
    1. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Japanese Journal of Surgery. 1981;11(2):127–139.
    1. Bonenkamp J, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. The Lancet. 1995;345(8952):745–748.
    1. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Lancet. 1996;347(9007):995–999.
    1. Biffi R, Chiappa A, Luca F, et al. Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer: low morbidity and mortality rates in a single center series of 250 patients. Journal of Surgical Oncology. 2006;93(5):394–400.
    1. Roviello F, Marrelli D, Morgagni P, et al. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. Annals of Surgical Oncology. 2002;9(9):894–900.
    1. Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F. Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian gastric cancer study group prospective multicenter surgical study. Journal of Clinical Oncology. 1998;16(4):1490–1493.
    1. Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. European Journal of Surgical Oncology. 2004;30(3):303–308.
    1. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer. 1998;1:10–24.
    1. Japanese Gastric Cancer Association. Japanese Classification of Gastric Cancer. 14th edition. Tokyo, Japan: Kanehara & Co. Ltd; 2010.
    1. Maruyama K, Sasako M, Kinoshita T, et al. Should systematic lymph node dissection be recommended for gastric cancer? European Journal of Cancer. 1998;34(10):1480–1489.
    1. Japanese Gastric Cancer Association. Gastric Cancer Treatment Guidelines. Tokyo, Japan: Kanehara & Co. Ltd; 2010.
    1. Greene FL, Page DL, Fleming ID, editors. AJCC Cancer Staging Manual: TNM Classification of Malignant Tumors. 6th edition. New York, NY, USA: Springer; 2002.
    1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Handbook. 7th edition. New York, NY, USA: Springer; 2010.
    1. Hartgritik HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. Journal of Clinical Oncology. 2004;22(11):2069–2077.
    1. Bunt AMG, Hermans J, Boon MC, et al. Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer. Journal of Clinical Oncology. 1994;12(2):417–422.
    1. Songun I, Putter H, Kranenbarg EMK, Sasako M, van de Velde CJH. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet Oncology. 2010;11(5):439–449.
    1. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 dissections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. British Journal of Cancer. 1999;79:1522–1530.
    1. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. The Lancet Oncology. 2006;7(4):309–315.
    1. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. British Journal of Surgery. 2004;91(3):283–287.
    1. Isozaki H, Okajima K, Fujii K, et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepato-Gastroenterology. 1999;46(25):549–554.
    1. Baba M, Hokita S, Natsugoe S, et al. Paraaortic lymphadenectomy in patients with advanced carcinoma of the upper-third of the stomach. Hepato-Gastroenterology. 2000;47(33):893–896.
    1. Kunisaki C, Shimada H, Yamaoka H, et al. Indications for paraaortic lymph node dissection in gastric cancer patients with paraaortic lymph node involvement. Hepato-Gastroenterology. 2000;47(32):586–589.
    1. Takashima S, Kosaka T. Results and controversial issues regarding a para-aortic lymph node dissection for advanced gastric cancer. Surgery Today. 2005;35(6):425–431.
    1. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. The The New England Journal of Medicine. 2008;359(5):453–462.
    1. Chen XZ, Hu JK, Zhou ZG, et al. Meta-analysis of effectiveness and safety of D2 plus para-aortic lymphadenectomy for resectable gastric cancer. Journal of the American College of Surgeons. 2010;210(1):100–105.
    1. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. American Journal of Surgery. 2007;193(1):10–15.
    1. Yonemura Y, Wu CC, Fukushima N, et al. Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: a prospective randomized trial conducted by Asian surgeons. Hepato-Gastroenterology. 2006;53(69):389–394.
    1. Yonemura Y, Wu CC, Fukushima N, et al. East Asia Surgical Oncology Group. Randomized clinical trial of D2 and extended paraaaortic lymph adenectomy in patients with gastric cancer. International Journal of Clinical Oncology. 2008;13:132–137.
    1. Wang Z, Chen JQ, Cao YF. Systematic review of D2 lymphadenectomy versus D2 with para-aortic nodal dissection for advanced gastric cancer. World Journal of Gastroenterology. 2010;16(9):1138–1149.
    1. Koufuji K, Shirouzu K, Aoyagi K, et al. Surgery and clinicopathological features of gastric adenocarcinoma involving the esophago-gastric junction. Kurume Medical Journal. 2005;52(3):73–79.
    1. Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncology. 2006;7(8):644–651.
    1. Okajima K, Isozaki H. Splenectomy for treatment of gastric cancer: Japanese experience. World Journal of Surgery. 1995;19(4):537–540.
    1. Noguchi Y, Imada T, Matsumoto A, Coit DG, Brennan MF. Radical surgery for gastric cancer. A review of the Japanese experience. Cancer. 1989;64(10):2053–2062.
    1. Kitamura K, Nishida S, Ichikawa D, et al. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. British Journal of Surgery. 1999;86(1):119–122.
    1. Kodera Y, Yamamura Y, Shimizu Y, et al. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. World Journal of Surgery. 1997;21(6):622–628.
    1. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K. Pancreas-preserving total gastrectomy for proximal gastric cancer. World Journal of Surgery. 1995;19(4):532–536.
    1. Furukawa H, Hiratsuka M, Ishikawa O, et al. Total gastrectomy with dissection of lymph nodes along the splenic artery: a pancreas-preserving method. Annals of Surgical Oncology. 2000;7(9):669–673.
    1. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501. Journal of Clinical Oncology. 2004;22(14):2767–2773.
    1. Clavien PA, Sarr MG, Fong Y. Atlas of upper gastrointestinal and hepato-pancreatico-biliary surger. In: Sasako M, editor. Total Gastrectomy with Radical Systemic Lymphadenectomy. New York, NY, USA: Springer; 2007. pp. 179–188.
    1. Yoshino K, Yamada Y, Asanuma F, Aizawa K. Splenectomy in cancer gastrectomy: recommendation of spleen-preserving for early stages. International Surgery. 1997;82(2):150–154.
    1. Ikeguchi M, Kaibara N. Lymph node metastasis at the splenic hilum in proximal gastric cancer. American Surgeon. 2004;70(7):645–648.
    1. Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery. 2002;131(4):401–407.
    1. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. British Journal of Surgery. 2006;93(5):559–563.
    1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England Journal of Medicine. 2006;355(1):11–20.
    1. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. The New England Journal of Medicine. 2007;357(18):1810–1820.
    1. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA—Journal of the American Medical Association. 2010;303(17):1729–1737.
    1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376(9742):687–697.

Source: PubMed

3
订阅